| Patent Number |
Title Of Patent |
Date Issued |
| RE40183 |
7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
March 25, 2008 |
| The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula ##STR00001## wherein R, X, R.sup.5 and R.sup.6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics. |
| RE40086 |
Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl- |
February 19, 2008 |
| The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline. |
| 7419982 |
Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-- |
September 2, 2008 |
| The present invention relates to crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-- trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts; processes for the production thereof; pharmaceutical compositions thereof; and method |
| 7384640 |
Mutant cholera holotoxin as an adjuvant |
June 10, 2008 |
| A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a vertebrate host to a |
| 7374751 |
QS-21 and IL-12 as an adjuvant combination |
May 20, 2008 |
| Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. These composition |
| 7361355 |
Mutant forms of cholera holotoxin as an adjuvant |
April 22, 2008 |
| Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera ho |
| 7344724 |
UspA1 and UspA2 antigens of Moraxella catarrhalis |
March 18, 2008 |
| The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than |
| 7332174 |
Mutant forms of cholera holotoxin as an adjuvant |
February 19, 2008 |
| Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate h |
| 7316917 |
Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixt |
January 8, 2008 |
| The invention relates to an enzymatic process for the production of an intermediate, bicyclic-heteroaryl-2-carboxylic acid 7, of the formula ##STR00001## wherein X and Y are defined in the specification and which are useful in the preparation of beta-lactamase inhibitors, by selective |
| 7297795 |
Process for preparation of 4-amino-3-quinolinecarbonitriles |
November 20, 2007 |
| This invention discloses a process for the preparation of a 4-amino-3-quinolinecarbonitrile comprising combining an amine compound with a cyanoacetic acid and an acid catalyst to yield a cyanoacetamide; condensing the cyanoacetamide with an optionally up to tetra-substituted aniline |
| 7285555 |
6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents |
October 23, 2007 |
| This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cance |
| 7285281 |
Mutant forms of cholera holotoxin as an adjuvant |
October 23, 2007 |
| Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera ho |
| 7282496 |
Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
October 16, 2007 |
| Compounds of the formula ##STR00001## are useful in treating disease conditions mediated by TNF-.alpha., such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, graft rejection, cachexia, infla |
| 7276611 |
Process for synthesizing beta-lactamase inhibitor intermediates |
October 2, 2007 |
| There is provided a process for the preparation of bicyclicheteroaryl carboxaldehydes having the structural Formula I where X and Y are defined in the specification ##STR00001## The bicyclic heteroaryl carboxaldehydes are useful as intermediates in the preparation of .beta.-lactamase |
| 7238345 |
Recombinant microorganism expressing meningococcal class 1 outer membrane protein |
July 3, 2007 |
| Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease. |
| 7229983 |
4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] subst |
June 12, 2007 |
| The present invention relates to novel, low molecular weight broad spectrum compounds in particular to a class of 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid or their derivatives which have .beta.-lactam |
| 7223854 |
Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV), p |
May 29, 2007 |
| The present invention provides a purified preparation containing a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome v |
| 7223408 |
Human papillomavirus polypeptides and immunogenic compositions |
May 29, 2007 |
| The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these |
| 7211417 |
Antibiotic P175-A and semisynthetic derivatives thereof |
May 1, 2007 |
| This invention relates to a new antibiotic designated P175-A, to production of fermentation of Micromonospora echinospora NRRL 30633, to methods for recovery and concentration from the crude solutions, and to a process for purification and to semisynthetic esters and ethers of P175-A |
| 7211260 |
Infectious bursitis vaccine |
May 1, 2007 |
| The present invention is concerned with isolated infectious bursitis (or bursal) disease virus(es) and a vaccine containing said virus(es) which is capable of protecting poultry against disease caused by infectious bursitis virus, characterized in that the vaccine virus(es) has/have the |
| 7199155 |
Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
April 3, 2007 |
| Hydroxamic acids having the formula ##STR00001## are useful in treating disease conditions mediated by TNF-.quadrature., such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of |
| 7129266 |
Antibiotic Cyan426-A |
October 31, 2006 |
| The invention relates to a new antibiotic designated Cyan426-A, to its production by fermentation, to methods for its recovery and concentration from the crude solutions, and to a process for its purification and to semisynthetic ethers of Cyan426-A, Cyan426-A-ethers. |
| 7118757 |
Meningococcal class 1 outer-membrane protein vaccine |
October 10, 2006 |
| Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease. |
| 7078572 |
Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
July 18, 2006 |
| The invention is a process for the preparation of compounds of the Formula I: ##STR00001## where R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are defined in the specification, which are intermediates useful for the preparation of tubulin inhibitors which are useful in the treatment of |
| 7078556 |
Antibiotics Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D and Cyan-416 E, and ester derivatives |
July 18, 2006 |
| The invention relates to new antibiotics designated Cyan-416A, Cyan 416B, Cyan-416C, Cyan-416D and Cyan-416E to their production by fermentation of Acremonium sp. NRRL 30631 to methods for recovery and concentration from the crude solutions, and to a process for purification and to s |
| 7078195 |
Antibiotics AA-896 |
July 18, 2006 |
| This invention relates to new antibiotics designated AA-896-A1, AA-896-A2, AA-896-A3, AA-896-A4, AA-896-A5, AA-896-A6, AA-896-Bl, AA-896-B2, AA-896-B3, AA-896-B4, AA-896-B5, AA-896-B6, AA-896-B7, AA-896-C1, AA-896-C2, AA-896-C3, AA-896-C4, AA-896-C5, AA-896-D1, AA-896-D2, AA-896-D3 a |
| 7034141 |
Packaging of positive-strand RNA virus replicon particles |
April 25, 2006 |
| The invention generally relates to recombinant polynucleotides, positive-strand RNA virus (psRNAV) recombinant expression vectors, and packaging systems. The packaging systems are based on the expression of helper functions by coinfecting recombinant poxvirus vectors comprising recom |
| 7022873 |
Antibiotics Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D and Cyan-416 E, and ester derivatives |
April 4, 2006 |
| The invention relates to new antibiotics designated Cyan-416A, Cyan 416B, Cyan-416C, Cyan-416D and Cyan-416E to their production by fermentation of Acremonium sp. NRRL 30631 to methods for recovery and concentration from the crude solutions, and to a process for purification and to s |
| 7019014 |
Process for producing anticancer agent LL-D45042 |
March 28, 2006 |
| The disclosure describes the production of anticancer agent LL-D45042, having the structure: ##STR00001## by fermentation, to methods for the recovery and concentration of this anticancer agent from crude solutions, and to processes for the purification of this anticancer agent as well |
| 7018996 |
Antibiotics AW998A, AW998B, AW998C and AW998D |
March 28, 2006 |
| This invention relates to antibiotics selected from the group AW998A, AW998B, AW998C and AW998D derived from the microorganism Streptomyces designated LL-AW998, which are useful as antibacterial agents. |
| 6995001 |
Processing for preparing monoprotected diols from symmetric diols |
February 7, 2006 |
| This invention provides a two-step enzymatic process for the synthesis of monoprotected diols from symmetric diols. |
| 6964860 |
Glycopeptide antibiotics |
November 15, 2005 |
| The invention provides compounds of formula ##STR1##Wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.6d, R.sup.6e and R.sup.7 are defined in the specification. These compounds are useful as antibiotic agents. |
| 6951955 |
Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
October 4, 2005 |
| The invention is a process for the preparation of compounds of the Formula I: ##STR1##where R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are defined in the specification, which are intermediates useful for the preparation of tubulin inhibitors which are useful in the treatment of c |
| 6949661 |
3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition o |
September 27, 2005 |
| The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for t |
| 6946473 |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroary |
September 20, 2005 |
| Compounds of the formula ##STR1##which are useful in disease conditions mediated by TNF-.alpha., such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss. |
| 6942802 |
Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatograph |
September 13, 2005 |
| The present invention relates to the purification of polypeptides and the removal of endotoxin via immobilized metal affinity chromatography (IMAC). More specifically, the invention relates to methods for removing bacterial endotoxin in a protein solution. In specific embodiments, the in |
| 6933388 |
Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolones |
August 23, 2005 |
| There is provided a process for the preparation of 3-cyano-6-alkoxy-7-nitro-4-quinolone intermediates useful for the preparation of protein tyrosine kinase (PTK) inhibitors which are useful in the treatment of cancer of the formula: ##STR1##wherein R is alkyl(C.sub.1 -C.sub.3) prepar |
| 6914045 |
Glycopeptide antibiotics |
July 5, 2005 |
| The invention provides compounds of formula ##STR1##Wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.6d, R.sup.6e and R.sup.7 are defined in the specification. These compounds are useful as antibiotic agents. |
| 6900184 |
Compositions containing pipercillin and tazobactam useful for injection |
May 31, 2005 |
| The invention pertains to pharmaceutical compositions of Zosyn.RTM. piperacillin with tazobactam in the presence of a buffer, preferably citrate, a particulate formation inhibitor, preferably EDTA optionally an aminoglycoside which when frozen and thawed or lyophilized and reconstitu |
| 6899885 |
74-kilodalton outer membrane protein from Moraxella catarrhalis |
May 31, 2005 |
| A protein from M. catarrhalis, designated the 74 kD protein, is isolated and purified. The 74 kD protein has an amino-terminal amino acid sequence which is conserved among various strains of M. catarrhalis. The protein has a molecular weight of approximately 74.9 kD as measured on a 10% |
| 6878737 |
Reversal of multidrug resistance in human colon carcinoma cells |
April 12, 2005 |
| The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs. |
| 6867000 |
Method of enhancing immune responses to herpes |
March 15, 2005 |
| A method for inducing and enhancing protective and/or therapeutic immunity in a mammal to HSV includes the steps of at least one immunization with an effective amount of a DNA vaccine composition which comprises a first nucleic acid molecule comprising a DNA sequence encoding the HSV typ |
| 6861445 |
3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of |
March 1, 2005 |
| The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for t |
| 6858591 |
Antibiotic AA 896 analogs |
February 22, 2005 |
| The invention provides compounds of the Formula 1 ##STR1##wherein the definitions of m, n, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 and R.sup.13 are in the specification. These compounds are useful as antibacterial |
| 6841160 |
Meningococcal vaccines formulated with interleukin-12 |
January 11, 2005 |
| This invention pertains to vaccine compositions comprising a mixture of antigen, such as pneumococcal or meningococcal antigen, and interleukin IL-12, which may be adsorbed onto a mineral in suspension. The pneumococcal or meningococcal antigen may be conjugated to a carrier molecule |
| 6825354 |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and TACE inhibitors |
November 30, 2004 |
| Compounds of the formula ##STR1##are useful in treating disease conditions mediated by TNF-.alpha., such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss. |
| 6821988 |
3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases |
November 23, 2004 |
| This invention provides compounds of Formula (I), represented by the structure ##STR1##wherein G.sub.1, G.sub.2, G.sub.3, G.sub.4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic |
| 6812227 |
Acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
November 2, 2004 |
| Compounds of the formula: ##STR1##are useful in treating disease conditions mediated by TNF-.alpha., such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss. |
| 6784184 |
5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhi |
August 31, 2004 |
| This invention relates to a method of using novel 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones of Formula (I), wherein Ar, Ar', R.sub.6, m and n are as defined in the specification as inhibitors of Ras FPTase, and may be used as an alternative to, |
| 6780996 |
Process for the preparation of 7-substituted-3 quinolinecarbonitriles |
August 24, 2004 |
| There is provided a process for the preparation of 7-substituted-3-quinolinecarbonitriles and intermediates useful in a process to prepare 7-substituted-3-quinolinecarbonitriles and pharmaceutically acceptable salts is described. Where 7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitri |
